We Offer Worldwide Shipping
Login Wishlist

Ursodeoxycholic acid


  • Brand : BIOFRON

  • Catalogue Number : BF-U2001

  • Specification : 98%

  • CAS number : 128-13-2

  • Formula : C24H40O4

  • Molecular Weight : 392.57

  • PUBCHEM ID : 31401

  • Volume : 20mg

In stock

Checkout Bulk Order?

Catalogue Number


Analysis Method






Molecular Weight



White crystalline powder

Botanical Source

Ursus thibetanus

Structure Type



Standards;Natural Pytochemical;API




(3a,5b,7b,8x)-3,7-dihydroxycholan-24-oic acid/Ursofalk/17b-(1-Methyl-3-carboxypropyl)etiocholane-3a,7b-diol/3α,7β-Dihydroxy-6β-cholan-24-oic acid/Ursolvan/Ursochol/Peptarom/(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-Dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid/Actigall/Delursan/Ursodeoxycholic acid/(3α,5β,7β)-3,7-Dihydroxycholan-24-oic acid/3a,7b-dihydroxy-5b-cholan-24-oic acid/(3α,5β,7β,8ξ,20R)-3,7-Dihydroxycholan-24-oic acid/Cholan-24-oic acid, 3,7-dihydroxy-, (3α,5β,7β)-/Litursol/Cholit-ursan/(3a,5b,7b)-3,7-dihydroxy-cholan-24-oic acid/3,7-Dihydroxycholan-24-oic acid/3α,7β-dihydroxy-5β-cholan-24-oic acid/(3a,5b,7b)-3,7-Dihydroxycholan-24-oic Acid/cholan-24-oic acid, 3,7-dihydroxy-, (3a,5b,7b,8x)-/Ursacol/Ursodiol/Cholan-24-oic acid, 3,7-dihydroxy-, (3α,5β,7β,8ξ,20R)-/3a,7b-Dioxycholanic Acid/Destolit/3alpha,7beta-Dihydroxy-6beta-cholan-24-oic acid/Arsacol


(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid


1.1±0.1 g/cm3


Methanol; Ethanol

Flash Point

298.8±19.7 °C

Boiling Point

547.1±25.0 °C at 760 mmHg

Melting Point

203-206 ºC


InChl Key

WGK Germany


HS Code Reference


Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:128-13-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate




The off-label use of medications is a “right” for pediatricians, owing to lack of enough safety and effectiveness drug trials in pediatric age group. Pediatricians have to rely on their personal judicial use of medications in children.We studied off-label use of ursodeoxycholic acid (UDCA) retrospectively during 2005 to 2015 among those who attended the Pediatic Hepatology Unit, Cairo University.We analyzed data of 779 neonates and infants with cholestasis. 15% dropped out. Males comprised 374 (56.5%). Cholestasis was due to surgical causes in 129 (19.5%), neonatal hepatitis in 445 (67.2%), and paucity of intrahepatic bile ducts in 88 (13.3%). Three hundred sixty (54.4%) received UDCA (15-30 mg/kg/d), and 302 (45.6%) did not. Both groups were matched as regards causes and severity of cholestasis. Those who received UDCA had worse outcome (P < .001), and more complications (P < .001). A total of 73.1% (221) achieved cure without UDCA compared to only 45.8% (165) of those on UDCA (P < .001).UDCA is not effective and not safe in Egyptian neonates and infants with cholestasis. UDCA use compromises chance of cure, and is associated with serious morbidity, progression of disease, and death. UDCA off-label use mortality was absolutely preventable. Off- label use of UDCA in neonates and children should be utterly prohibited. Information of use of off-label medications, effectiveness, and safety, should be recorded, analyzed, and made available within context of Off-label Use Registry Studies with informed consent of parents.


Ursodeoxycholic acid use is associated with significant risk of morbidity and mortality in infants with cholestasis: A strobe compliant study.


Kotb MA1, Mosallam D1, Basanti CWS1, El Sorogy STM2, Badr AM1, Abd El Baky HEH1, Draz IH1.

Publish date

2020 Feb




Prolonged cholestasis is a rare complication associated with endoscopic retrograde cholangiopancreatography (ERCP).

A 68-year-old man who presented with worsening cholestasis after ERCP for the removal of a common bile duct stone.

Total bilirubin increased up to 35.2 mg/dL after the 21st day post-ERCP. A percutaneous liver biopsy was performed and drug-related cholestasis was suspected as occurring as a result of the contrast agent.

Oral ursodeoxycholic acid and cholestyramine were prescribed to the patient.

By the 7th week post-ERCP, the patient’s symptoms and markers of physiological health began to resolve. The bilirubin returned to normal levels on the 106th day post-ERCP. We reviewed the literature for studies of 9 patients with jaundice more than 30 days post-ERCP, the peak of total serum bilirubin occurred on 16th ± 7th days and the recovery followed after mean time of 54th ± 22th days.

Although the cholestasis was prolonged, the outcome was favorable after medical therapy. There were no long-term consequences for the patient.


Prolonged cholestasis following endoscopic retrograde cholangiopancreatography, a rare complication of contrast agent induced liver injury: A case report and literature review.


Lin CK1, Huang WC2.

Publish date

2020 Jan




Chronic liver diseases such as hepatitis C or non-alcoholic fatty liver disease could be associated with insulin resistance, even in the absence of cirrhosis or significant fibrosis. In this report, we present the case of a patient who was diagnosed with primary biliary cholangitis and metabolic syndrome. Initial evaluation also revealed diabetes with elevated fasting plasma glucose and glycated hemoglobin. After eight weeks of treatment with ursodeoxycholic acid, a complete normalization of the hepatic biological tests was observed. A few months later, while body weight and abdominal perimeter remained stable, fasting blood glucose and glycated hemoglobin decreased significantly, compatible with diabetes disappearance. This finding supports the concept that the inflamed liver plays a major role in the pathogenesis of insulin resistance and diabetes occurrence in chronic liver diseases, including primary biliary cholangitis.

© Acta Gastro-Enterologica Belgica.


diabetes; insulin resistance; liver inflammation; macrophages; primary biliary cholangitis; ursodeoxycholic acid


Impact of liver inflammation on whole body insulin resistance : a case report on primary biliary cholangitis.


Clarembeau F1,2, Komuta M3, Horsmans Y1,2, Lanthier N1,2.

Publish date

2019 Oct-Dec

Description :

Ursodiol reduces cholesterol absorption and is used to dissolve gallstones.Target: OthersUrsodiol, also known as ursodeoxycholic acid and the abbreviation UDCA, is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria. The drug reduces cholesterol absorption and is used to dissolve (cholesterol) gallstones in patients who want an alternative to surgery. The drug is very expensive, however, and if the patient stops taking it, the gallstones tend to recur if the condition that gave rise to their formation does not change. For these reasons, it has not supplanted surgical treatment by cholecystectomy.Ursodeoxycholic acid is currently the only established drug for the treatment of chronic cholestatic liver diseases. It has cytoprotective, anti-apoptotic, membrane stabilizing, anti-oxidative and immunomodulatory effects. Prolonged administration of ursodeoxycholic acid in patients with primary biliary cirrhosis (PBC) is associated with survival benefit and a delaying of liver transplantation.